Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Axcella Health Inc
(NQ:
AXLA
)
4.580
UNCHANGED
Last Price
Updated: 4:00 PM EST, Nov 22, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Axcella Health Inc
< Previous
1
2
Next >
Axcella Therapeutics to Present at the H.C. Wainwright BioConnect Conference
January 04, 2022
From
Axcella Therapeutics
Via
Business Wire
Axcella Therapeutics Announces Initiation of AXA1125 Long COVID Phase 2a Clinical Trial
December 16, 2021
From
Axcella Therapeutics
Via
Business Wire
Axcella Therapeutics Promotes Margaret Koziel, M.D., to Chief Medical Officer
December 06, 2021
From
Axcella Therapeutics
Via
Business Wire
Axcella Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference
November 18, 2021
From
Axcella Therapeutics
Via
Business Wire
Axcella Therapeutics Reports Third Quarter Financial Results and Provides Update on Long COVID, OHE and NASH Clinical Trials
November 10, 2021
From
Axcella Therapeutics
Via
Business Wire
Axcella Therapeutics Announces Upcoming Presentations at AASLD’s The Liver Meeting® 2021
November 02, 2021
From
Axcella Therapeutics
Via
Business Wire
Axcella Therapeutics Launches Clinical Program to Develop Treatment for Patients with Long COVID
October 26, 2021
From
Axcella Therapeutics
Via
Business Wire
Axcella, Now Axcella Therapeutics, to Host Virtual R&D Day on October 26, 2021
October 19, 2021
From
Axcella Therapeutics
Via
Business Wire
Axcella Announces Upcoming Investor Conference Presentation
October 05, 2021
From
Axcella
Via
Business Wire
Axcella Health Inc. (NASDAQ: AXLA) Featured in Coverage of Benzinga’s Healthcare Small Cap Conference
September 24, 2021
Via
Investor Brand Network
Topics
Derivatives
Exposures
Derivatives
Axcella Announces Upcoming Investor Conference Presentation
September 07, 2021
From
Axcella
Via
Business Wire
Axcella Announces Publication in The American Journal of Gastroenterology of Positive Results from AXA1125-003 in Subjects With Presumed NASH
August 16, 2021
From
Axcella
Via
Business Wire
Axcella Reports Second Quarter Financial Results and Provides Business Update
July 29, 2021
From
Axcella
Via
Business Wire
Axcella to Report Second Quarter 2021 Financial Results on July 29, 2021
July 22, 2021
From
Axcella
Via
Business Wire
Axcella Announces Initiation of EMMPOWER℠ Phase 2 Clinical Trial of AXA1665
June 30, 2021
From
Axcella
Via
Business Wire
Positive Clinical Data About Axcella’s AXA1665 Candidate for Overt Hepatic Encephalopathy Highlighted in Oral Presentation at DDW 2021
May 24, 2021
From
Axcella
Via
Business Wire
Axcella Announces Initiation of EMMPACT℠ Phase 2b Clinical Trial of AXA1125
May 11, 2021
From
Axcella
Via
Business Wire
Axcella Announces Initiation of EMMPACTSM Phase 2b Clinical Trial of AXA1125
May 11, 2021
From
Axcella
Via
Business Wire
Axcella Reports First Quarter Financial Results and Provides Business Update
May 06, 2021
From
Axcella
Via
Business Wire
Axcella to Report First Quarter 2021 Financial Results on May 6, 2021
April 27, 2021
From
Axcella
Via
Business Wire
Axcella Announces Upcoming Oral Presentation at Digestive Disease Week (DDW) 2021
April 22, 2021
From
Axcella
Via
Business Wire
Axcella Announces AXA1125’s IND Clearance for the Treatment of NASH
April 13, 2021
From
Axcella
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.